GlaxoSmithKline News and Research

RSS

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

The HIV Prevention Trials Network has launched two new phase 2 studies, HPTN 076 and HPTN 077, which are designed to evaluate new drugs to protect people from getting infected with HIV.

19 Feb 2015

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).

19 Feb 2015

Celon, Lupin sign definitive agreement to develop generic version of Advair Diskus

Pharma Major Lupin Limited (Lupin) and Celon Pharma S.A. (Celon) announced today that they have entered into a definitive agreement under which the companies will jointly develop a fluticasone/salmeterol dry powder inhaler (DPI) product which is a generic version of GlaxoSmithKline's Advair Diskus®.

17 Feb 2015

MedImmune, University of Manchester sign new research collaboration

MedImmune, the global biologics research and development arm of AstraZeneca, and The University of Manchester have entered into a new research collaboration to generate cutting-edge protein formulation science.

5 Feb 2015

Large clinical trial to assess safety, efficacy of two experimental Ebola vaccines opens in Liberia

A large clinical trial to assess the safety and efficacy of two experimental vaccines to prevent Ebola virus infection is now open to volunteers in Liberia. The trial is being led by a recently formed Liberia-U.S. clinical research partnership and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

3 Feb 2015

Efficacy of ebola vaccine to be assessed in large-scale clinical trial

GlaxoSmithKline (GSK) announced today that they will soon be commencing the first large-scale clinical trial to assess the efficacy of an experimental ebola vaccine.

23 Jan 2015

New collaborative project aims to generate 3% productivity boost at Australian pharmaceutical sites

META, a collaborative network of high potential manufacturing businesses and researchers, has today announced a collaborative project between Hospira, GlaxoSmithKline and CSL to generate a targeted 3% productivity boost with an estimated return on investment of up to $2.4M dollars at Australian pharmaceutical sites.

4 Dec 2014

Sanford-Burnham, Mayo Clinic scientists to jointly find new treatment for resistant hypertension

Sanford-Burnham Medical Research Institute at Lake Nona and Mayo Clinic today announced that a joint team of scientists has been selected as a winner of GlaxoSmithKline's 2014 Discovery Fast Track Challenge.

2 Dec 2014

Ebola vaccine shows promising results in human trial

An experimental vaccine against the Ebola virus has proved effective and well-tolerated in the first human trial of a candidate Ebola drug.

27 Nov 2014

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland.

27 Nov 2014

Merck, NewLink Genetics sign exclusive worldwide license agreement for Ebola vaccine candidate

Merck, known as MSD outside the United States and Canada, and NewLink Genetics Corporation, announced today that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV (Ebola) vaccine candidate.

24 Nov 2014

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets.

31 Oct 2014

Researchers identify compounds that could lead to discovery of new drugs for African sleeping sickness

In early drug discovery, you need a starting point, says Northeastern University associate professor of chemistry and chemical biology Michael Pollastri.

27 Oct 2014

Human trial of second investigational Ebola vaccine candidate under way

Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health's Clinical Center in Bethesda, Maryland.

23 Oct 2014

Viewpoints: Abortion and birth control issues in N.C. Senate race; replacing Obamacare; cancellations

But on Wednesday in Charlotte, Kay Hagan stood without hesitation next to Janet Colm, chief executive of the Planned Parenthood Action Fund of Central North Carolina, and proudly bashed her opponent, Thom Tillis, for reducing women's rights on abortion and birth control.

17 Oct 2014

Pharmaceutical firms share data to enhance transparency of clinical trials for new drugs

To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies.

16 Oct 2014

First study of promising Ebola vaccine commenced in West Africa

Professor Myron M. Levine, MD, Director of the Center for Vaccine Development at the University of Maryland School of Medicine, and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced today that the CVD, in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers (and other front-line workers) to evaluate a promising experimental Ebola vaccine.

10 Oct 2014

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

9 Oct 2014

BioCap conference showcased life sciences companies in the North

The unique BioCap conference organised by Bionow, a not for profit membership organisation for the biomedical / life-sciences industry, was a great success, combining the forces of science and financial investment enabling businesses from all over the North to secure essential funding.

3 Oct 2014

Early review: Open payments database not so open

The new federal website, which was created to provide information about financial links between physicians and the drug industry, is not user-friendly, notes The Associated Press. Meanwhile, The Wall Street Journal digs into the data to see what it shows about the ties between medical professionals and the drug industry.